Find out how AI influences drug discovery, enabling earlier predictions and reducing the risks in clinical development.

The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.

As biological data volume continues to grow, sequence-based AI is poised to become the dominant discovery layer across pharma, biotech, and industrial biology. Ainnocence is expanding partnerships, ...

AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...

NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to ...

FAR Biotech, a computational drug discovery company using proprietary quantum modeling and deep learning AI to tackle high impact diseases with significant unmet medical need, today announced that it ...

As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: ...

Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.

NVIDIA and its partners have, over recent days, unveiled a wave of new AI hardware and collaborations, from Blackwell-based ...

Speeding up drug discovery in the age of AI may come down to a concept that's comfortingly old-fashioned: Consulting a ...

Under the terms of the collaboration, Iktos will apply its generative AI and AI-orchestrated robotics platform to design, ...

insitro has acquired Israeli AI therapeutics company CombinAbleAI and launched its TherML platform, creating an end-to-end, ...